

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Savella under the patient's prescription drug benefit.

Description:

FDA-approved Indications

Savella is indicated for the management of fibromyalgia.

Savella is not approved for use in pediatric patients.

Applicable Drug List:

Savella

Policy/Guideline:

Coverage Criteria

<u>Fibromyalgia</u>

Authorization may be granted when the requested drug is being prescribed for the management of fibromyalgia when the following criteria is met:

• The patient is 18 years of age or older

Continuation of Therapy

Fibromyalgia

Authorization may be granted when the requested drug is being prescribed for the management of fibromyalgia when ALL of the following criteria are met:

- The patient is 18 years of age or older
- The patient has achieved or maintained a positive clinical response to the requested drug (e.g., improvement in pain)

Approval Duration and Quantity Restrictions:

Approval:

- Initial therapy: 6 months
- Renewals: 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits



References:

- 1. Savella [package insert]. North Chicago, IL: AbbVie Inc; December 2023.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed April 18, 2024.
- 3. Micromedex[®] (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 04/18/2024).